[Request for a compassionate use of biotherapies in oncology].
The introduction of targeted therapies since a few years has led to the rapid growth of biological agent use in oncology. Nevertheless, they are not available for all the categories of tumors. Moreover, the latest monoclonal antibody, bevacizumab, is currently only used at an early stage of the disease. Two new types of indications which are not yet admitted are emphasized in this review. The first one is the combination of bevacizumab and cetuximab in refractory metastatic colorectal cancer. The second one is the addition of bevacizumab to chemotherapy in metastatic tumors previously treated but still sensitive to chemotherapy. The collect of numerous observational studies is needed to bring evidence of efficacy and to justify the rapid use of these costly treatments for more patients.
Hauteville
Dominique
D
Service des maladies sanguines et tumorales, Hôpital Paul-Brousse, 12 avenue Paul Vaillant Couturier, BP 200.
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D001691:Biological Therapy / Q000379:methods*; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000473:pathology; D019008:Drug Resistance, Neoplasm; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000068818:Cetuximab; D005472:Fluorouracil